SCHEMBL20009100

SCHEMBL20009100

CCCc1cc(-c2cc(NC)c(C)cc2C)cc(N2CCCCC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 2/20 0.37
HTR6 P50406 2/20 0.36
DRD2 P14416 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
HTT P42858 4/20 0.36
MAPK1 P28482 4/20 0.36
MAPT P10636 3/20 0.36
GAA P10253 3/20 0.36
XBP1 P17861 1/20 0.36
KDM4E B2RXH2 3/20 0.35
TSHR P16473 1/20 0.35
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
L3MBTL1 Q9Y468 4/20 0.34
KMT2A Q03164 3/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20008538 0.74 DRD2 (0.49) HTR6DRD2ALDH1A1HPGDHSD17B10
SCHEMBL20009117 0.74 RAF1 (0.40) NUDT1ALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL19529392 0.68 RAF1 (0.40) HTR6DRD2ALDH1A1HPGDHSD17B10
SCHEMBL20008460 0.67 RAF1 (0.41) HTR6DRD2ALDH1A1HPGDHSD17B10
SCHEMBL12486712 0.67 SMN1; SMN2 (0.41) NUDT1ALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL12486046 0.65 HTT (0.44) ALDH1A1CYP1A2SMN1; SMN2HTTMAPK1
SCHEMBL26036874 0.63 PDE10A (0.62) PDE10A
SCHEMBL12486987 0.63 GALR2 (0.56) ALDH1A1HSD17B10SMN1; SMN2HTTMAPK1
SCHEMBL12484984 0.63 GALR2 (0.48) ALDH1A1SMN1; SMN2HTTMAPK1MAPT
SCHEMBL20009397 0.62 RAF1 (0.49) NUDT1ALDH1A1HPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299367-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS Novartis AG (CH) 2018-03-28 EP disclosed